Form 4: Electromed Director Kathleen Tune Receives 3,000 Restricted Shares

Electromed, Inc. Director Kathleen A. Tune was granted 3,000 shares of common stock as restricted stock, scheduled to vest on June 1, 2026.

Summary

• Kathleen A. Tune, a Director of Electromed, Inc. (ELMD), acquired 3,000 shares of common stock.
• The acquisition was a grant of restricted stock with a transaction price of $0 per share.
• These shares are scheduled to vest on June 1, 2026, subject to earlier acceleration or termination per their terms.
• Following this transaction, Ms. Tune beneficially owns 15,000 shares of Electromed, Inc. common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned acquisition.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is a positive sign of alignment between management and shareholders, indicating long-term commitment. It's a routine compensation event, not a major market mover, hence a moderately positive score.

Positives

• The grant of restricted stock to a director aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent acquisition.

Risks

• The vesting of the restricted stock is subject to terms that could lead to earlier acceleration or termination, introducing some uncertainty regarding the final ownership.

Future Outlook

The restricted stock grant with a future vesting date of June 1, 2026, indicates a long-term incentive for the director, aligning their future interests with the company's performance.

Industry Context

Director stock grants are a common form of executive and director compensation in publicly traded companies, particularly in the medical device or healthcare sector where Electromed operates. This practice aims to align leadership's financial interests with long-term shareholder value.

Comparison to Industry Standards

• Granting restricted stock to directors is a standard practice across various industries, including medical technology, to incentivize long-term commitment and performance.
• The $0 transaction price is typical for restricted stock grants, as it represents compensation rather than a purchase.
• Vesting periods, such as the one extending to June 1, 2026, are common for such grants, ensuring retention and performance alignment over several years.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as director compensation tied to stock performance aligns interests.

Next Steps

• The 3,000 restricted shares are scheduled to vest on June 1, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock to a director as part of their compensation. While it indicates alignment of interests, it does not present new information that would fundamentally alter the investment thesis for Electromed, Inc. Therefore, a "hold" recommendation is appropriate, as the filing itself doesn't provide a strong catalyst for buying or selling, but rather confirms standard corporate governance practices.

Keywords

Electromed, ELMD, Form 4, Insider Trading, Restricted Stock, Director Compensation, Stock Grant, Kathleen Tune, Corporate Governance